Author: Xodjanova, Sh.I.

Annotation: Timely laboratory diagnostics of aspirin resistance, which in clinical practice is based on objective clinical and laboratory criteria in patients receiving aspirin, is one of the problems that have not been completely solved by modern medicine. The aim of the study was to determine the aggregation activity of platelets in patients with ischemic heart disease and to evaluate the effect of aspirin on platelet aggregation. For the study, 116 patients were selected who were treated with a diagnosis of ischeamic heart disease with stable angina pectorisof functional class II–III. Patients who received aspirin before 1 year were included in group 1, patients who received aspirin from 1 year to 5 years were included in group 2 and patients who received aspirin for more than 5 years were included in group 3, as well as patients who did not receive aspirin were included in the control group. Spontaneous and ADP-induced platelet aggregations of 0.1, 1.0 and 5.0 mmol were evaluated. It was noted that all indicators of platelet aggregation were statistically significantly higher in patients of groups 1 and 2 treated with ASA than in patients who did not receive ASA in the control group (r<0.05). The level of platelet aggregation was lower in the control group of patients than in group 3 patients with a duration of aspirin intake of more than 5 years, but the differences were not statistically significant (p>0.05). The indicators of spontaneous and ADP-induced platelet aggregation of group 3 patients were higher than those of group 1 and 2 patients and statistically significant differences were observed in the indicators of group 1 patients (spontaneous aggregation of 1.7±0.09 r<0.05, 0.1 µm ADP-induced aggregation of 6.58±5.0 ADP-induced aggregation of 58.44±3.72 R1<0.01). The proportion of resistance to aspirin was 32.6%. To determine aspirin resistance in patients with coronary heart disease receiving aspirin, it is necessary to evaluate the functional activity of platelets by examining platelet aggregation. With an increase in the duration of taking aspirin in patients with coronary heart disease, the likelihood of resistance to aspirin increases, as well as antiplatelet activity increases.

Keywords: coronary heart disease, aspirin, platelet aggregation, aspirin resistance.

Pages in journal: 883 - 892